Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dyne Therapeutics, Inc. (Nasdaq: DYN) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Dyne is a clinical-stage biopharmaceutical company focused on genetically driven neuromuscular diseases, and its filings offer detailed insight into its programs, financing activities and risk disclosures.
Investors can review current reports on Form 8-K, where Dyne reports material events such as quarterly financial results, public offerings of common stock, loan and security agreements, regulatory designations for its product candidates and changes to its board of directors. For example, recent 8-K filings describe underwritten public offerings of DYN common stock, a term loan facility with Hercules Capital, Inc., Breakthrough Therapy Designation for DYNE-251, and director appointments.
Through Dyne’s registration statements and prospectus supplements referenced in its filings, users can track details of equity offerings made under its shelf registration on Form S-3. Filings also identify that DYN common stock is registered under Section 12(b) of the Exchange Act and listed on the Nasdaq Global Select Market.
On Stock Titan, these documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as financing terms, cash runway statements, clinical and regulatory milestones referenced in disclosure, and covenant structures in loan agreements. Users can follow new 8-Ks and other submissions as they are made available through EDGAR, and use the summarized content to orient themselves before consulting the full text of each filing.
Dyne Therapeutics, Inc. Chief Financial Officer Lucera Erick reported an open-market sale of 5,727 shares of common stock at a weighted average price of $18.64 per share. According to the disclosure, these shares were sold automatically to satisfy tax withholding obligations tied to restricted stock units that vested on March 31, 2025, under a pre-established agreement treated as a binding contract consistent with Rule 10b5-1. Following the transaction, Erick holds 125,373 shares, including 114,575 unvested restricted stock units, indicating this was a routine, tax-driven event rather than a discretionary trade.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of 2,000 shares of common stock. The shares were bought at a weighted average price of $17.08 per share on this transaction date, with individual trade prices ranging from $17.06 to $17.10. Following this purchase, Posner directly holds 15,500 Dyne Therapeutics shares.
Dyne Therapeutics Inc ownership update: The Vanguard Group filed an amended Schedule 13G/A stating it reports no beneficial ownership of Dyne Therapeutics common stock following an internal realignment. The filing lists Amount beneficially owned: 0 and Percent of class: 0%.
The filing cites an internal realignment effective January 12, 2026 and is signed on 03/26/2026.
Dyne Therapeutics director Brian S. Posner purchased additional shares of the company. On March 11, 2026, he made an open-market purchase of 2,000 shares of Dyne Therapeutics common stock at a price of $19.35 per share. Following this transaction, he directly owns 13,500 shares.
Dyne Therapeutics, Inc. director Dirk Kersten reported an indirect open-market sale of 129,672 shares of common stock at a weighted average price of $19.5151 per share. The sale was executed by ForDyne B.V. under a Rule 10b5-1 trading plan adopted on November 11, 2025.
Following the transaction, ForDyne holds 4,644,386 Dyne Therapeutics shares. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. and Forbion Growth Opportunities Fund II Cooperatief U.A. Kersten disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Dyne Therapeutics, Inc. director-associated entity ForDyne B.V. reported open-market sales of a total of 688,788 shares of Dyne common stock over March 9–10, 2026. The sales were executed at weighted average prices, with disclosed ranges from $17.50 to $20.03 per share. Following these transactions, entities associated with the reporting person continued to hold 4,774,058 Dyne shares indirectly. The filing notes that the March 2026 sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by ForDyne on November 11, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
DYN: ForDyne B.V. reported dispositions of Common Stock on 03/09/2026 and 03/10/2026
The filing shows sales of 177,690 shares with proceeds of $3,148,986.64 on 03/09/2026 and 511,098 shares with proceeds of $10,000,336.60 on 03/10/2026.
Dyne Therapeutics, Inc. director Brian S. Posner purchased 3,000 shares of common stock in an open-market transaction. The weighted average purchase price was $15.06 per share, with individual trade prices ranging from $14.96 to $15.12. Following this purchase, he directly owns 11,500 shares.